NewcelX Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $17.1M
- Price
- $2.96
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.52%
- Volume
- 7.2K
About
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Quick stats
Shares outstanding5.8M
Computed float3.0M
Float / shares51.8%
Cash runway (months)1.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001783036
Websitehttps://newcelx.net
AI Summary
AI-generated1/9
minorneutraloperations update
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
NewcelX management will attend the Breakthrough T1D Clinical & Research Congress in Philadelphia on October 9-11, 2026, with meetings available for researchers, investors, and potential partners.
The company will discuss its lead program NCEL-101, a stem-cell-derived pancreatic islet cell therapy combined with Eledon's tegoprubart, ahead of a planned Phase 1/2a trial in Type 1 Diabetes.
The update reiterates a constructive FDA Type B Pre-IND meeting from July 2026 and notes remaining IND-enabling work; no new data, financial figures, or regulatory actions were disclosed.
The release's risk language reiterates substantial doubt about the company's ability to continue as a going concern and Nasdaq listing compliance risks.
Red flags
- forward-looking statements disclose substantial doubt about going concern
- risk of failing to maintain Nasdaq listing compliance
- preclinical-stage company with no clinical data yet; trial still subject to IND submission